Halozyme Therapeutics Inc
NASDAQ:HALO

  • LAST PRICE
    49.9200
  • TODAY'S CHANGE (%)
    -1.2400 (-2.4238%)
  • Bid / Lots
    48.4800/ 1
  • Ask / Lots
    49.9200/ 10
  • Open / Previous Close
    50.8400 / 51.1600
  • Day Range
    49.5300
    51.2200
  • 52 Week Range
    32.7800
    53.0000
  • Volume
    1,286,707

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
HALO
Halozyme Therapeutics Inc
6.5B
20.6x
---
IONS
Ionis Pharmaceuticals Inc
5.7B
-14.9x
---
ITCI
Intra-Cellular Therapies Inc
7.2B
-60.0x
---
BPMC
Blueprint Medicines Corp
6.5B
-21.9x
---
PTCT
PTC Therapeutics Inc
2.8B
-4.9x
---
APLS
Apellis Pharmaceuticals Inc
4.9B
-12.4x
---
As of 2024-06-11

Company Information

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Contact Information

Headquarters
12390 EL CAMINO REALSAN DIEGO, CA, United States 92130
Phone
858-794-8889
Fax
302-655-5049

Executives

Independent Chairman of the Board
Jeffrey Henderson
President, Chief Executive Officer, Director
Helen Torley
Chief Financial Officer, Senior Vice President
Nicole Labrosse
Senior Vice President, Chief Technical Officer
Michael Labarre
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Mark Snyder

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$6.5B
Revenue (TTM)
$863.0M
Shares Outstanding
127.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.25
EPS
$2.42
Book Value
$0.66
P/E Ratio
20.6x
Price/Sales (TTM)
7.5
Price/Cash Flow (TTM)
16.1x
Operating Margin
43.95%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.